Raymond James Financial Services Advisors Inc. Sells 2,868 Shares of DaVita Inc. (NYSE:DVA)

Raymond James Financial Services Advisors Inc. lessened its stake in DaVita Inc. (NYSE:DVA) by 15.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,491 shares of the company’s stock after selling 2,868 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in DaVita were worth $1,623,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of DVA. Norges Bank bought a new position in shares of DaVita in the fourth quarter valued at approximately $116,373,000. Deutsche Bank AG lifted its holdings in shares of DaVita by 421.8% in the third quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after purchasing an additional 885,195 shares in the last quarter. Amundi lifted its holdings in shares of DaVita by 226.3% in the fourth quarter. Amundi now owns 659,372 shares of the company’s stock valued at $52,592,000 after purchasing an additional 457,285 shares in the last quarter. Morgan Stanley lifted its holdings in DaVita by 37.9% during the fourth quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock worth $92,042,000 after acquiring an additional 339,051 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in DaVita by 912.4% during the fourth quarter. Point72 Asset Management L.P. now owns 338,139 shares of the company’s stock worth $25,249,000 after acquiring an additional 304,739 shares during the period. Institutional investors own 90.12% of the company’s stock.

Insider Activity

In other news, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the transaction, the insider now directly owns 81,297 shares in the company, valued at $9,814,986.81. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,540 shares of company stock worth $16,551,071. 1.40% of the stock is owned by corporate insiders.

DaVita Stock Performance

NYSE:DVA opened at $131.40 on Friday. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. The business has a fifty day simple moving average of $128.57 and a two-hundred day simple moving average of $107.66. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $141.54. The company has a market capitalization of $11.52 billion, a P/E ratio of 17.76, a P/E/G ratio of 1.19 and a beta of 1.04.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the business posted $1.11 earnings per share. On average, analysts expect that DaVita Inc. will post 9.23 earnings per share for the current year.

Analysts Set New Price Targets

DVA has been the topic of a number of recent analyst reports. StockNews.com upgraded DaVita from a “buy” rating to a “strong-buy” rating in a report on Monday. UBS Group lifted their price target on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Barclays assumed coverage on DaVita in a report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price target on the stock. Finally, Truist Financial raised their target price on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, DaVita has a consensus rating of “Moderate Buy” and a consensus target price of $118.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.